Comparing the current results to its competitors, Phio Pharmaceuticals reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 15.15 %, recorded in the same quarter.
Phio Pharmaceuticals's Comment on Competition and Industry Peers
The biotechnology and pharmaceutical industries, including the immuno-oncology sector, are characterized by rapid evolution and significant competition. Competitors encompass large and small pharmaceutical and biotechnology companies, academic institutions, government agencies, and other private and public research organizations. Many of these competitors possess greater financial resources and human capital to develop competing products.
March 13, 2024
Phio Pharmaceuticals, a leading pharmaceutical company, has recently announced the addition of three renowned clinical trial sites that are now actively participating in the Phase 1b study. The Banner MD Anderson Cancer Center, The George Washington University, and Integrity Research have joined the existing site, broadening the geographical reach of the study across the United States. This significant development demonstrates the company s commitment to advancing medical research and the potential for new treatment options in cancer therapy.The Phase 1b Study:The Phase 1b study conducted by Phio Pharmaceuticals focuses on investigating the efficacy and safety profile of their groundbreaking therapeutic inte...
Publicly Traded Peers of Phio Pharmaceuticals Corp
Milestone Pharmaceuticals Inc Share Performance
-45.03%
One Year
Milestone Pharmaceuticals Inc
Profile
Milestone Pharmaceuticals Inc. is a pharmaceutical company that focuses on developing and commercializing innovative therapies for cardiovascular diseases. Their business model revolves around identifying unmet medical needs in the cardiovascular space and leveraging their expertise in drug development to create novel treatments. By conducting rigorous research, clinical trials, and collaborations, Milestone Pharmaceuticals aims to bring effective and safe medications to market, positively impacting patients' lives.
Praxis Precision Medicines Inc's business model revolves around developing precision medicines for the treatment of various central nervous system (CNS) disorders.
Ideaya Biosciences Inc operates on a precision medicine approach that combines genomics and synthetic lethality to develop targeted cancer therapies. The company focuses on identifying synthetic lethal interactions in cancer and leveraging these insights to discover and develop drugs that selectively target cancer cells. They collaborate with academic institutions and industry partners to advance their therapeutic pipeline and bring innovative treatments to patients in need.
Merus N V is a biotechnology company that operates using a differentiated and competitive business model. Their approach involves strategically targeting and developing bispecific antibodies to treat various types of cancer, leveraging their proprietary technologies and expertise in the field. By focusing on innovative research, efficient drug discovery, and partnerships, they aim to improve patient outcomes and drive growth in the oncology market.
Xoma Corporation operates under a business model focused on the development and commercialization of novel therapeutics. The company primarily concentrates on creating antibody-based therapies to address unmet medical needs. Xoma also engages in collaborations and partnerships with other pharmaceutical companies to advance their product pipeline and expand their reach in the market.
Sources:
Phio Pharmaceuticals Corp’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Phio Pharmaceuticals Corp versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
